GT Biopharma (GTBP) Amortization of Deferred Charges (2013 - 2024)
GT Biopharma (GTBP) posted quarterly Amortization of Deferred Charges of $26000.0 for Q1 2024, up 4.0% year-over-year from $25000.0 in Q2 2023, and down 23.53% quarter-over-quarter from $34000.0 in Q4 2023.
GT Biopharma (GTBP) Amortization of Deferred Charges (2013 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Amortization of Deferred Charges for 10 consecutive years, with $26000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Amortization of Deferred Charges rose 4.0% year-over-year to $26000.0; the TTM figure through Mar 2024 stood at $113000.0 (up 16.49% YoY), while the FY2023 annual figure was $112000.0, up 17.89% from the prior year.
- Amortization of Deferred Charges declined to $26000.0 in Q1 2024 per GTBP's latest filing, from $34000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $34000.0 in Q4 2023 and bottomed at $23000.0 in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $25888.9 across 3 years, with a median of $25000.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges jumped 36.0% — and 2024, when it climbed 4.0%.
- GT Biopharma's Amortization of Deferred Charges stood at $25000.0 in 2022, then jumped by 36.0% to $34000.0 in 2023, then decreased by 23.53% to $26000.0 in 2024.
- Business Quant data shows GTBP's Amortization of Deferred Charges at $26000.0 in Q1 2024, $34000.0 in Q4 2023, and $27000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 26,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 34,000.00 |
| Dec 31, 2023 | 34,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Dec 31, 2019 | 1.14 Mn |
| Dec 31, 2019 | 1.14 Mn |